8-K: AirSculpt Reports 2025 Results, Eyes 2026 Stabilization

AirSculpt Technologies announced its full year 2025 results, showing revenue and case volume declines, but reported sequential improvement in Q4 and positive same-store sales in February 2026.

Summary

• Full year 2025 revenue declined 15.8% to $151.8 million from $180.4 million in 2024.
• Full year 2025 case volume decreased 15.6% to 11,852 from 14,036 in 2024.
• Full year 2025 net loss widened to $11.7 million compared to $8.0 million in 2024.
• Full year 2025 Adjusted EBITDA decreased to $15.1 million from $21.0 million in 2024.
• Fourth quarter 2025 revenue declined 14.6% to $33.4 million, while case volume fell 15.0% to 2,604.
• Fourth quarter 2025 net loss improved to $1.3 million compared to $5.0 million in the prior year.
• Fourth quarter 2025 Adjusted EBITDA increased to $2.5 million from $1.9 million in the prior year.
• The company projects full year 2026 revenue between $151 million and $157 million and Adjusted EBITDA between $15 million and $17 million.
• First quarter 2026 revenue is expected to be $38.5 million to $39.5 million, representing same-store revenue of approximately flat at the midpoint.
• Gross debt was reduced to approximately $45.0 million in Q1 2026 after raising $14.8 million from an at-the-market offering and paying down $11.0 million of debt.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging report with significant year-over-year declines in key metrics, though Q4 showed some sequential improvement and debt reduction is positive. The 2026 outlook suggests stabilization rather than strong growth, reflecting ongoing market headwinds.

Positives

• Fourth quarter 2025 Adjusted EBITDA increased to $2.5 million from $1.9 million in the prior year.
• Fourth quarter 2025 net loss improved to $1.3 million compared to a $5.0 million loss in the prior year.
• Sequential improvement in same-store sales was observed in Q4 2025 compared to the first nine months of the year.
• Same-store sales turned positive in February 2026.
• Enhanced financial flexibility was achieved through a debt reduction to approximately $45.0 million in Q1 2026.
• Strategic steps were taken in 2025, including adding talent, improving business processes, implementing a new go-to-market strategy, and adding new procedures.

Negatives

• Full year 2025 revenue declined 15.8% to $151.8 million from $180.4 million in 2024.
• Full year 2025 case volume decreased 15.6% to 11,852 from 14,036 in 2024.
• Full year 2025 net loss widened to $11.7 million compared to $8.0 million in 2024.
• Full year 2025 Adjusted EBITDA decreased to $15.1 million from $21.0 million in 2024.
• Fourth quarter 2025 revenue declined 14.6% to $33.4 million from $39.2 million in the prior year.
• Fourth quarter 2025 case volume declined 15.0% to 2,604 from 3,064 in the prior year.
• The company incurred $2.2 million in costs related to the closure of its London facility in 2025.

Risks

• Inability to sell equity or other securities in the future at a time when the company might otherwise wish to effect sales.
• Inability to raise capital on commercially reasonable terms, if at all.
• Risk that any future financings may dilute stockholders or restrict business operations.
• Failure to stabilize same-store performance.
• Not being able to optimize marketing investment, go-to-market strategy, and sales process.
• Not having the ability to expand financing options for consumers.
• Being unsuccessful in further product innovations.
• Failure to operate centers in a cost-effective manner.
• Increased operating expenses due to rising inflation.
• Increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability, and customer awareness of weight-loss drugs.
• Shortages or quality control issues with third-party manufacturers or suppliers.
• Competition for surgeons.
• Litigation or medical malpractice claims.
• Inability to protect the confidentiality of proprietary information.
• Changes in the laws governing the corporate practice of medicine or fee-splitting.
• Changes in regulatory and macroeconomic conditions, including inflation and the threat of recession, economic and other conditions of the states and jurisdictions where facilities are located.
• Business disruption or other losses from natural disasters, war, pandemic, terrorist acts, or political unrest.

Future Outlook

The company projects full year 2026 revenue to be approximately $151 million to $157 million and Adjusted EBITDA to be approximately $15 million to $17 million. For the first quarter of 2026, revenue is expected to be $38.5 million to $39.5 million, with same-store revenue anticipated to be approximately flat at the midpoint.

Management Comments

• "In the fourth quarter, we delivered sequential improvement in same store sales versus the first nine months of the year and adjusted EBITDA ahead of the prior year period."
• "During 2025, we took significant steps to enhance our business approach and team. We added talent, improved business processes, implemented a new go-to-market strategy, and added new procedures that expanded our market potential."
• "We entered fiscal 2026 with same-store sales turning positive in February and enhanced financial flexibility to fuel our growth."
• "AirSculpt is scaled, trusted and strongly positioned at the intersection of aesthetics and GLP-1s. I'm confident our strategy positions us to create meaningful value for our shareholders."

Industry Context

StockSavvy.ai notes that AirSculpt's performance reflects broader challenges in the elective aesthetic procedures market, potentially exacerbated by macroeconomic pressures and the rising popularity of GLP-1 weight-loss drugs, which the company explicitly acknowledges as a competitive factor. The strategic pivot to enhance business processes and introduce new procedures, alongside debt reduction, indicates an adaptation to these evolving market dynamics.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for continued volatility due to declining revenue and widening net losses, offset by strategic adjustments and debt reduction. The ATM offering could lead to dilution.
• Employees: Strategic changes, including adding talent and improving processes, suggest ongoing operational adjustments. The closure of the London facility indicates some workforce impact.
• Customers: Introduction of new procedures aims to expand market potential and enhance offerings.
• Creditors: Debt reduction in Q1 2026 improves the company's financial flexibility and reduces leverage.

Next Steps

• Hold a conference call on April 2, 2026, at 8:30 am (Eastern Time) to discuss results.
• Annual Meeting of Stockholders to be held on May 12, 2026.
• Continue to implement new go-to-market strategy and new procedures.
• Focus on stabilizing same-store performance and optimizing marketing investment.

Key Dates

Recommendation

While AirSculpt Technologies reported significant declines in full-year 2025 revenue and net income, the sequential improvement in Q4 Adjusted EBITDA and positive same-store sales in February 2026 suggest a potential stabilization. The debt reduction in Q1 2026 is a positive step for financial flexibility. However, the competitive landscape, particularly with GLP-1 drugs, and the modest 2026 outlook indicate that a strong recovery is not yet assured. Investors should hold to observe if the strategic initiatives translate into sustained positive performance and if the company can effectively navigate industry headwinds.

Keywords

AirSculpt Technologies, AIRS, body contouring, aesthetics, cosmetic procedures, financial results, earnings, Q4 2025, full year 2025, 2026 outlook, Adjusted EBITDA, revenue, net loss, case volume, GLP-1s, debt reduction, SEC filing